Liposomal Bupivacaine for Postoperative Pain After Craniotomy
Status
Conditions
Treatments
Details and patient eligibility
About
Acute postoperative pain is a common postoperative adverse reaction. It refers to acute pain that occurs immediately after surgery and usually lasts no longer than 3-7. Among the craniotomy approaches, patients undergoing supratentorial craniotomy with temporal approach had a higher incidence of moderate to severe pain within 24 hours. In the management of postoperative acute pain, multimodal analgesia is recommended. Liposomal bupivacaine was encapsulated by liposomal vesicles and released slowly, lasting up to 72 hours. The long action time also makes the time window of postoperative acute pain completely covered, thus helping patients better control pain. At present, there is an obvious lack of clinical studies on the effectiveness and specific duration of liposome bupivacaine for postoperative acute pain, especially in neurosurgical craniotomy population with transtemporal incision approach, which is a high-risk group for postoperative pain in neurosurgery.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age 18-65 years old;
- Patients undergoing craniotomy tumor resection via frontotemporal approach, temporal base approach or temporal occipital approach;
- ASA grade I ~ III;
- Sign informed consent.
Exclusion criteria
- Previous history of combined drug allergy;
- Patients with a history of severe chronic pain;
- Long-term history of analgesic drug use;
- Patients with aphasia and other inability to cooperate with the scale were evaluated;
- Patients with mental system diseases;
- Patients with incomplete function of vital organs (heart, lung, liver, kidney);
- History of drug and drug abuse;
- BMI≥35kg/m2;
- Pregnant or lactating patients.
Trial design
Primary purpose
Allocation
Interventional model
Masking
106 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal